|
The CCPPRB committee, whose members are university professors,
ensures the law is applied to protect in-patients or
out-patients who accept to have new innovative products tested
on them.
The CCPPRB authorized the tests of BMN prototypes and classified
them in the category: tests with direct individual benefit for
the patient.
The study was managed in the department of the ‘functional
Explorations of the nervous system and Acupuncture,
multidisciplinary Consultations of pain’, Head of Department D
PRAT, in the Hospital complex and University of Nimes-Montpellier.
The tests have, therefore, mainly checked the therapeutic
benefit to human beings of an innovative device, the BMN, in
conformity with French and European pharmacopoeia criteria and
respecting international standards, that is to say:
Q To exclude intradermal, intramuscular or sub-cutaneous needles
in mésopuncture.
Q To have an easy-to-handle, miniaturized device causing less
pain due to the smaller diameter of the needle, the material the
reservoir is made of and the capacity adapted to the small
diameter of this needle making it possible to eliminate the
painful excess pressure phenomena upon injection.
Q To combine, in a single act, treatment by acupuncture and the
contribution of micro doses of selected active product according
to the pathology.
Q To notably reduce the quantity of remedies for the same
affection thanks to a better active product
quantity/effectiveness ratio: each depression of the reservoir
injecting
in loco only 2 or 3 drops (sucked into the reservoir prior to
use).
Q To equitably distribute the total volume of the drug ampule
into micro amounts of equal volume.
Q To locally inject micro doses of drug allowing a more precise
saturation of the membranous receptors, thereby avoiding the
hepatic path. Q To test the reliability of the BMN in
mesopuncture, in other words, to check that it allows to suck
up, store, and restore 2 or 3 drops of drug due to its intrinsic
and functional qualities, and in a totally harmlessness way. |